Science · From the edition of Jul 19, 2026
✳ Dated THURSDAY, JULY 1, 2027 ✳
PSILOCYBIN CLEARS FDA FOR DEPRESSION
Compass Pathways' COMP360 becomes the first psychedelic approved for treatment-resistant patients
WASHINGTON, July 1 — The FDA approved psilocybin for treatment-resistant depression on Thursday, an outcome traders had priced at 78 per cent. The magic-mushroom compound is now a prescription drug.
The molecule is COMP360, a synthetic version of the chemical that gives mushrooms their kick. Compass Pathways spent years running trials on patients who had failed everything else. The wires called it a turning point.
Delivery comes with guardrails: a single dose, taken in a clinic, with a therapist in the room. Millions have run out of options. As of Thursday, they have one more.
Source: Kalshi · 78% probability — View market ↗